What are you looking for?
Need help finding what you are looking for? Contact Us

PUBLISHER: FirstWord Group | PRODUCT CODE: 1480021

Cover Image

PUBLISHER: FirstWord Group | PRODUCT CODE: 1480021

Breast Cancer - Triple Negative - KOL Insight

DELIVERY TIME: 1-2 business days
Multi User License (PDF)
USD 39950

Add to Cart

From the growing enthusiasm for a potential subcutaneous formulation of Keytruda, the cautious optimism surrounding the outcomes of Cosela's PRESERVE 2 trial, and the promising future of datopotamab deruxtecan, explore the forefront of triple-negative breast cancer (TNBC) treatment advancements. KOLs provide a comprehensive analysis on the evolving landscape of TNBC therapy, emphasizing the significant impact these developments could have on patient care and treatment outcomes. Discover how these innovations are poised to transform the TNBC treatment paradigm.

In addition to the full report, licensed users have access to the following KOL Bulletins and special reports via the attachments area.

Key brands covered in this report:

  • Lynparza (olaparib)
  • Talzenna (talazoparib)
  • Tecentriq (atezolizumab)
  • Keytruda (pembrolizumab)
  • Trodelvy (sacituzumab govitecan)
  • Enhertu (trastuzumab deruxtecan)
  • Bavencio (avelumab)
  • veliparib
  • Piqray (alpelisib)
  • Zejula (niraparib)
  • Cosela (trilaciclib)
  • datopotamab deruxtecan

Key questions answered:

  • Which drug is the treatment of choice for each patient segment, line of therapy and unique patient characteristic, and what product attributes contribute to the preference?
  • How is the product perceived by the medical community in terms of efficacy, tolerability, ease of administration and other product attributes, and how does it compare with other treatment options?
  • Which recently completed or ongoing clinical trials have the greatest potential to impact prescribing trends, and how will the results impact practice in the future (e.g. PERSEVERE, neoBREASTIM, OptimICE-PCT, PRESERVE 2, ASCENT-03, ASCENT-04, ASCENT-05, TROPION-Breast04, TROPION-Breast05, etc.)?
  • What will a product need to show in order to become the treatment of choice in a specific line of therapy, and is it likely that the product will meet these requirements?
  • How will the use of each product change in the future in terms of line of therapy and preference?
  • What will the pipeline products need to show in terms of efficacy and tolerability endpoints to effectively compete with current therapies, and what is the likelihood that they will achieve those endpoints?

Table of Contents

Executive summary (9)

Triple-negative breast cancer current and future treatment algorithm (1)

Research objectives (2)

Triple-negative breast cancer (91)

  • Marketed drugs (48)
    • Lynparza (olaparib; AstraZeneca/Merck & Co.) (6)
    • Talzenna (talazoparib; Pfizer) (6)
    • Tecentriq (atezolizumab; Roche) (10)
    • Keytruda (pembrolizumab; Merck & Co.) (8)
    • Trodelvy (sacituzumab govitecan; Gilead Sciences) (10)
    • Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo) (8)
  • Pipeline drugs (39)
    • Bavencio (avelumab; Merck Group) (6)
    • veliparib (ABT-888; AbbVie) (8)
    • Zejula (niraparib; GSK) (5)
    • Piqray (alpelisib; Novartis) (4)
    • Cosela (trilaciclib; G1 Therapeutics) (8)
    • datopotamab deruxtecan (AstraZeneca/Daiichi Sankyo) (8)
  • General future trends impacting treatment (4)
    • Key insights summary (4)

Appendix (4)

  • KOL details (4)
    • KOLs from North America (2)
    • KOLs from Europe (1)
Have a question?

Jeroen Van Heghe

Manager - EMEA



Christine Sirois

Manager - Americas


Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!